References
- 1. Barrera B, Otero JA, Egido E et al. The Anthelmintic Triclabendazole and Its Metabolites Inhibit the Membrane Transporter ABCG2/BCRP. Antimicrob Agents Chemother 2012; 56(7): 3535-3543.
- 2. Halferty L, Brennan GP, Trudgett A, Hoey L, Fairweather I. Relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Vet Parasitol 2009; 159:126–138.
- 3. González Canga A, Sahagún Prieto AM, José Diez Liébana M, Martínez NF, Vega MS, Vieitez JJ. The pharmacokinetics and metabolism of ivermectin in domestic animal species. Vet J 2009; 179: 25–37.
- 4. Lifschitz A, Virkel G, Ballent M, Sallovitz J, Lanusse C. Combined use of ivermectin and triclabendazole in sheep: In vitroand in vivo characterisation of their pharmacological interaction. Vet J 2009; 182: 261–268.
- 5. Stevenson CR, Mahoney RH, Fisara P, Strehlau G, Reichel MP. The efficacy of formulations of triclabendazole and ivermectin in combination against liver fluke (Fasciolahepatica) and gastro-intestinal nematodes in cattle andsheep and sucking lice species in cattle. Aust Vet J. 2002; 80(11): 698-701
- 6. International Committee for Harmonization. GUIDELINE FOR GOOD CLINICAL PRACTICE E6 (R1). https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf [retrieved March 22nd 2019]
- 7. The European Agency for the Evaluation of Medicinal Products. CVMP Guideline on the Conduct of Bioequivalence Studies for Veterinary Medicinal Products, EMA/CVMP/016/00-Rev.2.
- 8. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-2_en.pdf [retrieved March 22nd 2019]
- 9. The European Agency for the Evaluation of Medicinal Products. CVMP Guidelines for the Conduct of Bioequivalence Studies for Veterinary Medicinal Products, EMEA/CVMP/016/00-corr-FINAL.
- 10. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-conduct-bioequivalence-studies-veterinary-medicinal-products-revision-1_en.pdf [retrieved March 22nd 2019]
- 11. The European Agency for the Evaluation of Medicinal Products. VICH GL52 Bioequivalence: Blood Level Bioequivalence Study, EMA/CMVP/VICH/751935/2013-Corr. https://www.ema.europa.eu/en/documents/scientific-guideline/international-cooperation-harmonisation-technical-requirements-registration-veterinary-medicinal_en-3.pdf [retrieved March 22nd 2019]
- 12. http://kineticadownload.com/Kinetica5.0/data/Kinetica%20User%20Manual.pdf [retrieved March 22nd 2019]
- 13. U.S. Department of Health and Human Services, Food and Drug Administration, Bioavailability and Bioequivalence Studies for Orally Administrated Drug Products – General Considerations, Rockville, USA, 2003, https://www.fda.gov/downloads/Drugs/Guidances/ucm154838 [retrieved March 22nd 2019]
- 14. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence, London, UK, 2001 (CPMP/EWP/QWP/1401/98). https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-investigation-bioavailability-bioequivalence_en.pdf [retrieved March 22nd 2019]
- 15. The European Agency for the Evaluation of Medicinal Products. Guideline on bioanalytical method validation (EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf [retrieved March 22nd 2019]
- 16. U.S. Department of Health and Human Services, Food and Drug Administration. Bioanalytical Method ValidationGuidance for Industry. https://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf [retrieved March 22nd 2019]